Bullous pemphigoid burden of disease, management and unmet therapeutic needs.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
15
02
2024
accepted:
15
08
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
19
9
2024
Statut:
aheadofprint
Résumé
Bullous pemphigoid (BP) is an autoimmune blistering disease that can have a profound negative impact on quality of life. BP most often affects the elderly, a population with a high medical burden and special safety concerns. In this review, we outline the BP disease course, diagnosis, epidemiology and comorbidities, and describe tools commonly used to assess BP disease activity and severity and the impact of BP on health-related quality of life. We also outline biologic treatments currently under investigation for the treatment of BP and highlight the importance of considering safety when treating elderly patients.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Regeneron Pharmaceuticals Inc.
Organisme : Sanofi
Informations de copyright
© 2024 Regeneron Pharmaceuticals. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology. This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA.
Références
Montagnon CM, Tolkachjov SN, Murrell DF, Camilleri MJ, Lehman JS. Subepithelial autoimmune blistering dermatoses: clinical features and diagnosis. J Am Acad Dermatol. 2021;85(1):1–14. https://doi.org/10.1016/j.jaad.2020.11.076
Kouris A, Platsidaki E, Christodoulou C, Armyra K, Korkoliakou P, Stefanaki C, et al. Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study. An Bras Dermatol. 2016;91(5):601–603. https://doi.org/10.1590/abd1806‐841.20164935
Bertram F, Bröcker E‐B, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–440. https://doi.org/10.1111/j.1610‐0387.2008.06976.x
Joly P, Baricault S, Sparsa A, Bernard P, Bédane C, Duvert‐Lehembre S, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132(8):1998–2004. https://doi.org/10.1038/jid.2012.35
Jung M, Kippes W, Messer G, Zillikens D, Rzany B. Increased risk of bullous pemphigoid in male and very old patients: a population‐based study on incidence. J Am Acad Dermatol. 1999;41(2):266–268. https://doi.org/10.1016/s0190‐9622(99)70061‐7
Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J. Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study. BMJ. 2008;337(7662):a180. https://doi.org/10.1136/bmj.a180
Marazza G, Pham HC, Schärer L, Pedrazzetti PP, Hunziker T, Trüeb RM, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2‐year prospective study. Br J Dermatol. 2009;161(4):861–868. https://doi.org/10.1111/j.1365‐2133.2009.09300.x
Zhao CY, Murrell DF. Advances in understanding and managing bullous pemphigoid. F1000Res. 2015;4:F1000 Faculty Rev‐1313. doi:10.12688/f1000research.6896.1
Wang EQ, Castrillón Velásquez MA, Murrell DF. The effects of autoimmune blistering diseases on work productivity: a review. Int J Womens Dermatol. 2018;4(3):131–138. https://doi.org/10.1016/j.ijwd.2017.11.001
Briand C, Gourier G, Poizeau F, Jelti L, Bachelerie M, Quéreux G, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study. Acta Derm Venereol. 2020;100(18):adv00320. https://doi.org/10.2340/00015555‐3683
Li F, Bian W, Wu Y, Zhu X, Chen X, Wang M. Bacterial skin infections in hospitalized patients with bullous pemphigoid. Adv Skin Wound Care. 2021;34(7):365–370. https://doi.org/10.1097/01.ASW.0000752704.10152.30
Baican A, Baican C, Chiriac G, Chiriac MT, Macovei V, Zillikens D, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in Northwestern Romania. Int J Dermatol. 2010;49(7):768–774. https://doi.org/10.1111/j.1365‐4632.2009.04345.x
Bernard P, Vaillant L, Labeille B, Bedane C, Arbeille B, Denoeux JP, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131(1):48–52.
Gudi VS, White MI, Cruickshank N, Herriot R, Edwards SL, Nimmo F, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North‐East Scotland. Br J Dermatol. 2005;153(2):424–427. https://doi.org/10.1111/j.1365‐2133.2005.06662.x
Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220. https://doi.org/10.3389/fmed.2018.00220
Bastuji‐Garin S, Joly P, Lemordant P, Sparsa A, Bedane C, Delaporte E, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case–control study. J Invest Dermatol. 2011;131(3):637–643. https://doi.org/10.1038/jid.2010.301
Kridin K, Bergman R. Ethnic variations in the epidemiology of bullous pemphigoid in Israel. Int J Dermatol. 2018;57(1):34–39. https://doi.org/10.1111/ijd.13813
Cole EF, Mustin DE, Feldman RJ. The effect of skin colour and Fitzpatrick skin type on Bullous Pemphigoid Disease Area Index (BPDAI) scores. Br J Dermatol. 2022;187(4):606–607. https://doi.org/10.1111/bjd.21648
Ren Z, Hsu DY, Brieva J, Silverberg NB, Langan SM, Silverberg JI. Hospitalization, inpatient burden and comorbidities associated with bullous pemphigoid in the U.S.A. Br J Dermatol. 2017;176(1):87–99. https://doi.org/10.1111/bjd.14821
Ong E, Goldacre R, Hoang U, Sinclair R, Goldacre M. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res. 2014;306(1):75–80. https://doi.org/10.1007/s00403‐013‐1399‐5
Schulze F, Neumann K, Recke A, Zillikens D, Linder R, Schmidt E. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol. 2015;135(5):1445–1447. https://doi.org/10.1038/jid.2014.547
Balestri R, Magnano M, La Placa M, Patrizi A, Angileri L, Tengattini V, et al. Malignancies in bullous pemphigoid: a controversial association. J Dermatol. 2016;43(2):125–133. https://doi.org/10.1111/1346‐8138.13079
Atzmony L, Mimouni I, Reiter O, Leshem YA, Taha O, Gdalevich M, et al. Association of bullous pemphigoid with malignancy: a systematic review and meta‐analysis. J Am Acad Dermatol. 2017;77(4):691–699. https://doi.org/10.1016/j.jaad.2017.05.006
Roujeau JC, Lok C, Bastuji‐Garin S, Mhalla S, Enginger V, Bernard P. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134(4):465–469. https://doi.org/10.1001/archderm.134.4.465
Lamberts A, Meijer JM, Pas HH, Diercks GFH, Horváth B, Jonkman MF. Nonbullous pemphigoid: insights in clinical and diagnostic findings, treatment responses, and prognosis. J Am Acad Dermatol. 2019;81(2):355–363. https://doi.org/10.1016/j.jaad.2019.04.029
Chen X, Zhao W, Jin H, Li L. Risk factors for mucosal involvement in bullous pemphigoid and the possible mechanism: a review. Front Med (Lausanne). 2021;8:680871. https://doi.org/10.3389/fmed.2021.680871
Murrell DF, Daniel BS, Joly P, Borradori L, Amagai M, Hashimoto T, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66(3):479–485. https://doi.org/10.1016/j.jaad.2011.06.032
Masmoudi W, Vaillant M, Vassileva S, Patsatsi A, Quereux G, Moltrasio C, et al. International validation of the Bullous Pemphigoid Disease Area Index severity score and calculation of cut‐off values for defining mild, moderate and severe types of bullous pemphigoid. Br J Dermatol. 2021;184(6):1106–1112. https://doi.org/10.1111/bjd.19611
Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17(1):4–11. https://doi.org/10.1684/ejd.2007.0090
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. https://doi.org/10.1111/j.1365‐2230.1994.tb01167.x
Herdman M, Gudex C, Lloyd A, Janssen MF, Kind P, Parkin D, et al. Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L). Qual Life Res. 2011;20:1727–1736. https://doi.org/10.1007/s11136‐011‐9903‐x
Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med. 1979;9(1):139–145. https://doi.org/10.1017/s0033291700021644
Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality‐of‐life instrument for patients with skin diseases. Arch Dermatol. 1997;133(11):1433–1440.
Padniewski JJ, Shaver RL, Schultz B, Pearson DR. Patient quality of life improvement in bullous disease: a review of primary literature and considerations for the clinician. Clin Cosmet Investig Dermatol. 2022;15:27–42. https://doi.org/10.2147/CCID.S324331
Borradori L, Van Beek N, Feliciani C, Tedbirt B, Antiga E, Bergman R, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36(10):1689–1704. https://doi.org/10.1111/jdv.18220
Yap E, Choon S, Murrell DF, Tey KE, Subramaniam P. Validation of the Malay version of Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire. In Proceedings of the 23rd Regional Conference of Dermatology (RCD 2018), p. 40–3. https://doi.org/10.5220/0008150300400043
Sebaratnam DF, Hanna AM, Chee S‐N, Frew JW, Venugopal SS, Daniel BS, et al. Development of a quality‐of‐life instrument for autoimmune bullous disease: the Autoimmune Bullous Disease Quality of Life questionnaire. JAMA Dermatol. 2013;149(10):1186–1191. https://doi.org/10.1001/jamadermatol.2013.4972
Tjokrowidjaja A, Daniel BS, Frew JW, Sebaratnam DF, Hanna AM, Chee S, et al. The development and validation of the treatment of autoimmune bullous disease quality of life questionnaire, a tool to measure the quality of life impacts of treatments used in patients with autoimmune blistering disease. Br J Dermatol. 2013;169(5):1000–1006. https://doi.org/10.1111/bjd.12623
Ferries L, Gillibert A, Duvert‐Lehembre S, Corbaux C, Alexandre M, Prost‐Squarcioni C, et al. Sensitivity to change and correlation between the autoimmune bullous disease quality‐of‐life questionnaires ABQOL and TABQOL, and objective severity scores. Br J Dermatol. 2020;183(5):944–945. https://doi.org/10.1111/bjd.19173
Yang B, Chen G, Yang Q, Yan X, Zhang Z, Murrell DF, et al. Reliability and validity of the Chinese version of the Autoimmune Bullous Disease Quality of Life (ABQOL) questionnaire. Health Qual Life Outcomes. 2017;15:1–6. https://doi.org/10.1186/s12955‐017‐0594‐z
Saleh MA, Zaraa I, Doss N, Saleh NA, Murrell DF. Assessment of the quality of life of Egyptian and Tunisian autoimmune bullous diseases' patients using an Arabic version of the autoimmune bullous disease quality of life and the treatment of autoimmune bullous disease quality of life questionnaires. An Bras Dermatol. 2019;94(4):399–404. https://doi.org/10.1590/abd1806‐4841.20197198
Teimourpour A, Hedayat K, Salarvand F, Ghandi N, Ghiasi M, Mahmoudi H, et al. Autoimmune Bullous Disease Quality of Life (ABQoL) questionnaire: validation of the translated Persian version in pemphigus vulgaris. Int J Womens Dermatol. 2020;6(4):306–310. https://doi.org/10.1016/j.ijwd.2020.03.043
Patsatsi A, Kokolios M, Kyriakou A, Lamprou F, Stylianidou D, Tsapas A, et al. Quality of life in Greek patients with autoimmune bullous diseases assessed with ABQOL and TABQOL indexes. Acta Derm Venereol. 2017;97(9):1145–1147. https://doi.org/10.2340/00015555‐2737
Kalinska‐Bienias A, Jakubowska B, Kowalewski C, Murrell DF, Wozniak K. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease‐specific Autoimmune Bullous Disease Quality of Life (ABQOL) and the Treatment Autoimmune Bullous Disease Quality of Life (TABQOL) questionnaires. Adv Med Sci. 2017;62(1):92–96. https://doi.org/10.1016/j.advms.2016.07.002
Lee S, Rastogi S, Hsu DY, Nardone B, Silverberg JI. Association of bullous pemphigoid and comorbid health conditions: a case‐control study. Arch Dermatol Res. 2021;313(5):327–332. https://doi.org/10.1007/s00403‐020‐02100‐2
Maronese CA, Cassano N, Genovese G, Foti C, Vena GA, Marzano AV. The intriguing links between psoriasis and bullous pemphigoid. J Clin Med. 2022;12(1):328. https://doi.org/10.3390/jcm12010328
Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population‐based case‐control study. J Invest Dermatol. 2011;131(3):631–636. https://doi.org/10.1038/jid.2010.357
Schmidt E, Borradori L, Joly P. Epidemiology of autoimmune bullous diseases. In: Murrell DF, editor. Blistering diseases. Berlin, Heidelberg: Springer; 2015. p. 51–63.
Ständer S, Hammers CM, Vorobyev A, Schmidt E, Hundt JE, Sadik CD, et al. Coexistence of bullous pemphigoid with neuropsychiatric comorbidities is associated with anti‐BP230 seropositivity. J Eur Acad Dermatol Venereol. 2021;35(10):2067–2073. https://doi.org/10.1111/jdv.17304
Taghipour K, Chi C‐C, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case‐control study. Arch Dermatol. 2010;146(11):1251–1254. https://doi.org/10.1001/archdermatol.2010.322
Kokkonen N, Herukka S‐K, Huilaja L, Kokki M, Koivisto AM, Hartikainen P, et al. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer's disease. J Invest Dermatol. 2017;137(1):71–76. https://doi.org/10.1016/j.jid.2016.09.010
Messingham KAN, Aust S, Helfenberger J, Parker KL, Schultz S, McKillip J, et al. Autoantibodies to collagen XVII are present in Parkinson's disease and localize to tyrosine‐hydroxylase positive neurons. J Invest Dermatol. 2016;136(3):721–723. https://doi.org/10.1016/j.jid.2015.12.005
Petrera MR, Tampoia M, Guida S, Abbracciavento L, Fumarulo R, Foti C. Bullous pemphigoid and neurologic diseases: toward a specific serologic profile? Endocr Metab Immune Disord Drug Targets. 2018;18(6):662–664. https://doi.org/10.2174/1871530318666180731115226
Wang Y, Mao X, Wang D, Hammers CM, Payne AS, Wang Y, et al. Anti‐BP180 autoantibodies are present in stroke and recognize human cutaneous BP180 and BP180‐NC16A. Front Immunol. 2019;10:236. https://doi.org/10.3389/fimmu.2019.00236
Teixeira VB, Cabral R, Brites MM, Vieira R, Figueiredo A. Bullous pemphigoid and comorbidities: a case‐control study in Portuguese patients. An Bras Dermatol. 2014;89(2):274–278. https://doi.org/10.1590/abd1806‐4841.20142516
Kluger N, Pankakoski A, Panelius J. Depression and anxiety in patients with bullous pemphigoid: impact and management challenges. Clin Cosmet Investig Dermatol. 2020;13:73–76. https://doi.org/10.2147/CCID.S212984
Dan J, Sprow G, Diaz D, Kodali N, Patel J, Vazquez T, et al. Bullous pemphigoid: comparing the prevalence and severity of itch and pain. J Am Acad Dermatol. 2023;89(1):159–160. https://doi.org/10.1016/j.jaad.2023.02.025
Kenna HA, Poon AW, de los Angeles CP, Koran LM. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011;65(6):549–560. https://doi.org/10.1111/j.1440‐1819.2011.02260.x
Liang Y, Zeng FAP, Sheriff T, Wilson A, Bilgic A, Feng G, et al. Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the Glucocorticoid Toxicity Index: a cohort study. JAAD Int. 2022;6:68–76. https://doi.org/10.1016/j.jdin.2021.09.003
Joly P, Roujeau J‐C, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321–327. https://doi.org/10.1056/NEJMoa011592
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen‐Housz‐Oro S, Bedane C, et al. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg−1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. Br J Dermatol. 2021;185(6):1232–1239. https://doi.org/10.1111/bjd.20593
Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18:513–528. https://doi.org/10.1007/s40257‐017‐0264‐2
Shenoy P, Harugeri A. Elderly patients' participation in clinical trials. Perspect Clin Res. 2015;6(4):184–189. https://doi.org/10.4103/2229‐3485.167099
Fairley JA, Baum CL, Brandt DS, Messingham KAN. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123(3):704–705. https://doi.org/10.1016/j.jaci.2008.11.035
Yu KK, Crew AB, Messingham KAN, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468–474. https://doi.org/10.1016/j.jaad.2014.04.053
Lieberman PL, Jones I, Rajwanshi R, Rosén K, Umetsu DT. Anaphylaxis associated with omalizumab administration: risk factors and patient characteristics. J Allergy Clin Immunol. 2017;140(6):1734–1736.e4. https://doi.org/10.1016/j.jaci.2017.07.013
Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156(2):352–356. https://doi.org/10.1111/j.1365‐2133.2006.07646.x
Kasperkiewicz M, Shimanovich I, Ludwig RJ, Rose C, Zillikens D, Schmidt E. Rituximab for treatment‐refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552–558. https://doi.org/10.1016/j.jaad.2010.07.032
Hall RP, Streilein RD, Hannah DL, McNair PD, Fairley JA, Ronaghy A, et al. Association of serum B‐cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133(12):2786–2788. https://doi.org/10.1038/jid.2013.236
Berkani N, Joly P, Golinski M‐L, Colliou N, Lim A, Larbi A, et al. B‐cell depletion induces a shift in self antigen specific B‐cell repertoire and cytokine pattern in patients with bullous pemphigoid. Sci Rep. 2019;9(1):3525. https://doi.org/10.1038/s41598‐019‐40203‐7
Immune Pharmaceuticals. Immune Pharmaceuticals presents updated positive results from phase 2 trial of bertilimumab in bullous pemphigoid. 2018. [cited 2024 Sep 6]. Available from: https://www.globenewswire.com/news‐release/2018/05/15/1502699/0/en/Immune‐Pharmaceuticals‐Presents‐Updated‐Positive‐Results‐from‐Phase‐2‐Trial‐of‐Bertilimumab‐in‐Bullous‐Pemphigoid.html
Simon D, Yousefi S, Cazzaniga S, Bürgler C, Radonjic S, Houriet C, et al. Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo‐controlled, double‐blind phase 2 pilot study. Allergy. 2020;75(3):669–672. https://doi.org/10.1111/all.13950
Rhyou H‐I, Han S‐H, Nam Y‐H. Successful induction treatment of bullous pemphigoid using reslizumab: a case report. Allergy Asthma Clin Immunol. 2021;17(1):1–4. https://doi.org/10.1186/s13223‐021‐00619‐1
ClinicalTrials.gov. A study to investigate the use of benralizumab in patients with bullous pemphigoid. (FJORD). [cited 2024 Sep 6]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04612790
Macdonald LE, Karow M, Stevens S, Auerbach W, Poueymirou WT, Yasenchak J, et al. Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes. Proc Natl Acad Sci USA. 2014;111(14):5147–5152. https://doi.org/10.1073/pnas.1323896111
Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci USA. 2014;111(14):5153–5158. https://doi.org/10.1073/pnas.1324022111
Kaye A, Gordon SC, Deverapalli SC, Her MJ, Rosmarin D. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018;154(10):1225–1226. https://doi.org/10.1001/jamadermatol.2018.2526
Saleh M, Reedy M, Torok H, Weaver J. Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature. Dermatol Online J. 2021;27(4):13030/qt0dv3f9h6.
Jafari SMS, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol. 2021;11:611549. https://doi.org/10.3389/fimmu.2020.611549
Abdat R, Waldman RA, de Bedout V, Czernik A, Mcleod M, King B, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. https://doi.org/10.1016/j.jaad.2020.01.089
Zhang Y, Xu Q, Chen L, Chen J, Zhang J, Zou Y, et al. Efficacy and safety of dupilumab in moderate‐to‐severe bullous pemphigoid. Front Immunol. 2021;12:738907. https://doi.org/10.3389/fimmu.2021.738907
Zhao L, Wang Q, Liang G, Zhou Y, Yiu N, Yang B, et al. Evaluation of dupilumab in patients with bullous pemphigoid. JAMA Dermatol. 2023;159(9):953–960. https://doi.org/10.1001/jamadermatol.2023.2428
Holtsche MM, Hammers CM, Chakievska L, Ludwig RJ, Thaci D, Zillikens D, et al. Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. J Dtsch Dermatol Ges. 2020;18(12):1478–1480. https://doi.org/10.1111/ddg.14291
Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T, et al. Secukinumab decreased circulating anti‐BP180‐NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol. 2019;46(6):e216–e217. https://doi.org/10.1111/1346‐8138.14760
Yun JS, Scardamaglia L, Tan C‐G, McCormack CJ. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. Australas J Dermatol. 2022;63(2):e155–e158. https://doi.org/10.1111/ajd.13803
Drenovska K, Valeva E, Shahid M, Vassileva S. Coexistence of bullous pemphigoid and psoriasis: therapeutic challenge and IL17A‐targeted parallel treatment strategy. Front Med (Lausanne). 2023;10:1148660. https://doi.org/10.3389/fmed.2023.1148660
Lu L, Yu Y, Zhang J, Fan X, Qi Y, Lin B. Incidental amelioration of bullous pemphigoid during ixekizumab treatment for psoriasis. J Dermatol. 2021;49(1):e13–e15. https://doi.org/10.1111/1346‐8138.16189
Cole C, Amber KT. Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL‐23 inhibition. J Eur Acad Dermatol Venereol. 2023;37(11):e1339–e1340. https://doi.org/10.1111/jdv.19317
Loget F, Plée P, Antonicelli F, Bernard P. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol Venereol. 2017;31(5):e228–e230. https://doi.org/10.1111/jdv.14002
Nash D, Kirchhof MG. Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib. JAAD Case Rep. 2023;32:81–83. https://doi.org/10.1016/j.jdcr.2022.12.006
Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor baricitinib. Dermatol Ther. 2022;35(10):e15754. https://doi.org/10.1111/dth.15754
Li H, Wang H, Qiao G, Liu Y, Zhang F, Pan F. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: a case report and review of the literature. Int Immunopharmacol. 2023;122:110591. https://doi.org/10.1016/j.intimp.2023.110591
Wijayanti A, Zhao CY, Boettiger D, Chiang YZ, Ishii N, Hashimoto T, et al. The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use? Acta Derm Venereol. 2017;97(1):24–31. https://doi.org/10.2340/00015555‐2473
Haddad E‐B, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther. 2022;2(7):1501–1533. https://doi.org/10.1007/s13555‐022‐00737‐7